Latest Conference Articles

Emory Healthcare Takes Charge of Specialty Pharmacy, Improves the Patient Experience

Tony Hagen

February 6 2020

In a recent presentation at the Specialty Therapies and Biosimilars Congress, the director of pharmacy for Emory Healthcare discussed how they developed a strong in-house specialty pharmacy and cut dependence on outside for-profit specialty pharmacies and managed to strengthen adherence, improve patient outcomes, and reduce costs.

CMS Payment Policy Plays Role in Biosimilar Uptake

Tony Hagen

January 30 2020

How does CMS payment policy for Medicare, Medicaid, and 340B hospitals affect biosimilar uptake? A speaker at the recent at the 2020 Specialty Therapies and Biosimilars Congress explained.

Trust, Planning Key to a Successful Biosimilar Launch, Panelists Say

Tony Hagen

January 24 2020

Panelists at the 2020 Specialty Therapies and Biosimilars Congress discussed the strategies needed to get biosimilars to market and overcome obstacles by originator product manufacturers.

Industry Executive Warns International Pricing Index Could Slow Drug Investment

Tony Hagen

January 24 2020

Molly Burich, MS, director of public policy for biosimilars and pipeline at the pharmaceutical giant Boehringer Ingelheim, discussed the International Price Index proposal Thursday at the 2020 Specialty Therapies and Biosimilars Congress in Miami, Florida.

Sputtering Cost Reforms May Gain Momentum in 2020, but Patients Will Still Carry Higher Burden

Tony Hagen

January 23 2020

In a wide-ranging state-of-the-industry talk, the clinical operations manager for Blue Cross Blue Shield of Michigan discussed pending legislation, electronic prior authorization (ePA), and biosimilar uptake, among other prominent issues Wednesday at the 2020 Specialty Therapies and Biosimilars Congress in Miami, Florida.

Biosimilar Makers Must Plan for Originator Firms Gaming the Patent System, Panel Says

Tony Hagen

January 22 2020

It’s important to keep in mind the successive patents that can be filed to keep an original product in a position of market dominance, and drug descriptions in biologic license applications can be written cleverly to achieve this aim, according to a panelist speaking at the Specialty Therapies and Biosimilars Conference, happening January 22-24, 2020, in Miami, Florida.

Celltrion Amps Up Its Biosimilar Launch Schedule

Tony Hagen

January 22 2020

The company's announcement of an aggressive launch calendar at the JP Morgan Healthcare Conference in San Francisco last week was followed by Celltrion’s announcement this week that it plans to open a large biologics manufacturing plant in Wuhan, China.

Teva's Schultz Sees Stability Ahead for US Biosimilar, Generic Marketplace

Mary Caffrey

January 15 2020

The leading generic drug manufacturer launched Truxima, a biosimilar for rituximab, in November 2019 at a 10% discount to the reference product, Rituxan.

Gilead Touts New Products in Revamped Growth Strategy

Tony Hagen

January 15 2020

Gilead Science’s new chairman and chief executive officer outlined a growth plan this week at the J.P. Morgan Healthcare Conference in San Francisco, California.

Studies Report on Switching, Tolerability, and Infection Risk With Biosimilar Infliximab

Kelly Davio

November 14 2019

As the only anti–tumor necrosis factor therapies currently available to US patients with inflammatory diseases, biosimilars of infliximab are increasingly used to treat diseases like rheumatoid arthritis. While there are a wealth of data on real-world use of these products in territories like the European Union, less research has examined their use in the United States. During the American College of Rheumatology’s 2019 meeting, held this week in Atlanta, Georgia, researchers reported on the results of 3 studies that assessed real-world use of biosimilar infliximab in the US context.